Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloperidone vs Risperidone in Schizophrenia
NCT02453893Phase 3Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of iloperidone in schizophrenia (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Positive and Negative Syndrome Scale at 8 weeks. Status: unknown.
02
Drugs
iloperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02453893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453893.